Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

ef="http://www.orexigen.com">www.orexigen.com.

Forward-Looking Statements Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding substantially lower cash expenditures for the second half of 2011 and increased expenditures in 2012, the protocol for, and the timing and feasibility of, the CVOT, the initiation of enrollment for the CVOT in the first half of 2012 and the engagement of a clinical research organization, a clear and feasible path forward for Contrave, and the potential for, and timing of, approval for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to come to an agreement with the FDA on the protocol for the CVOT, Orexigen's ability to initiate and conduct the CVOT and the progress and timing thereof, Orexigen's ability to demonstrate in the CVOT that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the CVOT; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resu
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Men’s skin is ... La-roche Posay ) and has been known to react ... some men may be far from puberty, other acne causing ... pores, causing breakouts, and threatening skin with unsightly acne scars. ... from Men’s Health on how to reduce and ...
(Date:5/17/2013)... CA (PRWEB) May 17, 2013 IAC Industries ... Technologies, a start up laboratory needing to set up and ... moving to a larger facility within a year’s time. How ... knowledge that the laboratory is temporary? What is efficient and ... Series modular workstations from IAC Industries. The planners at DisperSol ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... GBS and EV Expand GeneXpert(R) Test Menu in ... Cepheid (Nasdaq:,CPHD) today announced that Health Canada ... the rapid detection of Group B Streptococcus (GBS),and ... EV-associated,meningitis. These tests join Xpert MRSA, which received ...
... 3 American Oriental,Bioengineering (NYSE: AOB ) ... private,offer, subject to market conditions and other factors, ... of newly,issued convertible preferred stock. The convertible preferred ... arrears, and will be,convertible upon the occurrence of ...
... 3, 2008, TIME: 9:30 ... Dr. Candace Kendle, Chairman and CEO Kendle (Nasdaq: KNDL ... June 3 at 9:30 a.m. Eastern Time to,discuss the acquisition of ... provide an update on second quarter,progress. A question and answer session ...
Cached Biology Technology:Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 2Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 3Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 4American Oriental Bioengineering Announces Proposed Private Offering to Raise $125 Million via Convertible Preferred Stock 2Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress 2
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The AGA Research ... Augustyn and Damian Augustyn Award in Digestive Cancer, which ... School of Medicine at the University of Pennsylvania, Philadelphia, ... Zeb1 in pancreas development, regeneration and cancer progression. , ... award in honor of two distinguished clinicians and AGA ...
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... and Sustainable Global Logistics Operations) is aiming to cut ... of intermodal loading systems and the boosting of intelligent ... organisations with experience in the logistics sector and in ... and a duration of three and a half years. ... semantic components and ontologies shared by the users, objects ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... , PARIS , Feb. 4 ... Eurofins Scientific, a global leader in bio-analysis. , Under a ... connect 16 key Eurofins laboratories and research centers in ... company,s global customer base.  Verizon will use MPLS (multi-protocol label ...
... Toronto chemists have made a major contribution to the emerging ... photosynthesis in marine algae. "There,s been a lot of ... practices," says chemistry professor Greg Scholes, lead author of a ... "Our latest experiments show that normally functioning biological systems have ...
... College of Georgia researchers are seeking to refine cancer ... Chinese medicine. Celastrol, derived from trees and shrubs ... to treat symptoms such as fever, chills, joint pain ... play a role in cancer treatment by inactivating a ...
Cached Biology News:Verizon Business to Provide Global IP for Eurofins Scientific 2Verizon Business to Provide Global IP for Eurofins Scientific 3Scientists find quantum mechanics at work in photosynthesis 2Plant derivative could help refine cancer treatment 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Biology Products: